Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease

Author:

Vermunt Lisa1ORCID,Dicks Ellen1ORCID,Wang Guoqiao2,Dincer Aylin3,Flores Shaney3,Keefe Sarah J3,Berman Sarah B45,Cash David M6,Chhatwal Jasmeer P7,Cruchaga Carlos8910,Fox Nick C1112,Ghetti Bernardino13,Graff-Radford Neill R14,Hassenstab Jason151617,Karch Celeste M8,Laske Christoph1819,Levin Johannes20,Masters Colin L2122,McDade Eric1516,Mori Hiroshi23,Morris John C1516,Noble James M24,Perrin Richard J1525,Schofield Peter R2627,Xiong Chengjie2,Scheltens Philip1,Visser Pieter Jelle128,Bateman Randall J81516,Benzinger Tammie L S315,Tijms Betty M1ORCID,Gordon Brian A31517ORCID,Allegri Ricardo,Amtashar Fatima,Benzinger Tammie,Berman Sarah,Bodge Courtney,Brandon Susan,Brooks William,Buck Jill,Buckles Virginia,Chea Sochenda,Chrem Patricio,Chui Helena,Cinco Jake,Jack Clifford,D’Mello Mirelle,Donahue Tamara,Douglas Jane,Edigo Noelia,Erekin-Taner Nilufer,Fagan Anne,Farlow Marty,Farrar Angela,Feldman Howard,Flynn Gigi,Fox Nick,Franklin Erin,Fujii Hisako,Gant Cortaiga,Gardener Samantha,Ghetti Bernardino,Goate Alison,Goldman Jill,Gordon Brian,Gray Julia,Gurney Jenny,Hassenstab Jason,Hirohara Mie,Holtzman David,Hornbeck Russ,DiBari Siri Houeland,Ikeuchi Takeshi,Ikonomovic Snezana,Jerome Gina,Jucker Mathias,Kasuga Kensaku,Kawarabayashi Takeshi,Klunk William,Koeppe Robert,Kuder-Buletta Elke,Laske Christoph,Levin Johannes,Marcus Daniel,Martins Ralph,Mason Neal Scott,Maue-Dreyfus Denise,McDade Eric,Montoya Lucy,Mori Hiroshi,Nagamatsu Akem,Neimeyer Katie,Noble James,Norton Joanne,Perrin Richard,Raichle Marc,Ringman John,Roh Jee Hoon,Schofield Peter,Shimada Hiroyuki,Shiroto Tomoyo,Shoji Mikio,Sigurdson Wendy,Sohrabi Hamid,Sparks Paige,Suzuki Kazushi,Swisher Laura,Taddei Kevin,Wang Jen,Wang Peter,Weiner Mike,Wolfsberger Mary,Xiong Chengjie,Xu Xiong,

Affiliation:

1. Department of Neurology, Amsterdam Neuroscience, Alzheimer Center Amsterdam, Amsterdam, UMC, VU University, Netherlands

2. Division of Biostatistics, Washington University in St. Louis, MO, USA

3. Mallinckrodt Institute of Radiology, Washington University in St. Louis, MO, USA

4. Department of Neurology, Alzheimer’s Disease Research Center, Pittsburgh, PA

5. Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA

6. UCL Queen Square Institute of Neurology, London, UK

7. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

8. Department of Psychiatry, Washington University in St. Louis, MO, USA

9. Hope Center for Neurological Disorders, . Washington University in St. Louis, MO, USA

10. NeuroGenomics and Informatics, Washington University in St. Louis, St. Louis, MO, USA

11. Dementia Research Centre, Department of Neurodegenerative Disease, UK

12. Dementia Research Institute at UCL, UCL Institute of Neurology, London, UK

13. Department of Pathology and Laboratory Medicine, Indiana University, IN, USA

14. Mayo Clinic Florida, FL, USA

15. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, MO, USA

16. Department of Neurology, Washington University in St. Louis, MO, USA

17. Department of Psychological & Brain Sciences, Washington University in St. Louis, MO, USA

18. German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

19. Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Germany

20. Ludwig-Maximilians-Universität München, Germany

21. Florey Institute, Melbourne, Australia

22. The University of Melbourne, Melbourne, Australia

23. Department of Clinical Neuroscience, Osaka City University Medical School, Japan

24. Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, GH Sergievsky Center, Columbia University Medical Center, NY, USA

25. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis MO, USA

26. Neuroscience Research Australia, Sydney, Australia

27. School of Medical Sciences, UNSW Sydney, Sydney, Australia

28. Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Netherlands

Abstract

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.

Funder

Alzheimer Nederland Fellowship 2018

ZonMW Memorabel

Innovative Medicine Initiative – Joint Undertaking

European Union's Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations) EFPIA

Barnes Jewish Hospital Foundation

Dominantly Inherited Alzheimer Network

National Institute on Aging

German Center for Neurodegenerative Diseases

National Institutes of Health-funded National Institute of Neurological Disorders and Stroke (NINDS) Center Core for Brain Imaging

National Science Foundation

National Institutes of Health

the Swiss National Science Foundation

National Institute for Health Research University College London Hospitals Biomedical Research Centre

Medical Research Council (MRC) Dementias Platform UK

Publisher

Oxford University Press (OUP)

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference56 articles.

1. EU/US/CTAD Task Force: lessons learned from recent and current Alzheimer's prevention trials;Aisen;J Prev Alzheimers Dis,2017

2. Imaging structural co-variance between human brain regions;Alexander-Bloch;Nat Rev Neurosci,2013

3. The convergence of maturational change and structural covariance in human cortical networks;Alexander-Bloch;J Neurosci,2013

4. Human brain networks in health and disease;Bassett;Curr Opin Neurol,2009

5. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model;Bateman;Alzheimers Dement,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3